A freeze-dried pineapple extract—Brome-Inf, from pineapple by-products of industrial rings production, was enriched in bioactive polypeptides and bromelain by membrane ultrafiltration. Orchiepididymitis (OE), a painful pediatric pathology, was treated with this extract. A pilot, double-blind, randomized study involving 60 pediatric OE patients compared the effects of Brome-Inf to a placebo over a 15-day period, in conjunction with antibiotic treatment. In the present study, the primary objective was to assess the disparity in NSAIDs usage and pain intensity between the Brome-Inf group and the placebo group, utilizing the Wong-Becker, Numerical Rating Scale (NRS), and Visual Analogue Scale (VAS) pain rating scales. Results revealed a significant reduction in VAS and NRS within the Brome-Inf group from Days 1 to 15 compared with placebo. A rapid regression of edema was observed in the active group after 1 week and at the end of the study. We can conclude that oral supplementation with Brome-Inf emerges as a promising co-management option for OE for its action on pain and edema, potentially enhancing the quality of life for affected children. Importantly, due to its well-balanced fruity flavor, the palatability of Brome-Inf was appreciated, ensuring optimal patient compliance and treatment safety.

Bromelain‐Rich Pineapple Extract for the Treatment of Pediatric Patients With Orchiepididymitis: A Randomized Clinical Pilot Study

Colletti, Alessandro
First
;
Cravotto, Giancarlo
Last
2025-01-01

Abstract

A freeze-dried pineapple extract—Brome-Inf, from pineapple by-products of industrial rings production, was enriched in bioactive polypeptides and bromelain by membrane ultrafiltration. Orchiepididymitis (OE), a painful pediatric pathology, was treated with this extract. A pilot, double-blind, randomized study involving 60 pediatric OE patients compared the effects of Brome-Inf to a placebo over a 15-day period, in conjunction with antibiotic treatment. In the present study, the primary objective was to assess the disparity in NSAIDs usage and pain intensity between the Brome-Inf group and the placebo group, utilizing the Wong-Becker, Numerical Rating Scale (NRS), and Visual Analogue Scale (VAS) pain rating scales. Results revealed a significant reduction in VAS and NRS within the Brome-Inf group from Days 1 to 15 compared with placebo. A rapid regression of edema was observed in the active group after 1 week and at the end of the study. We can conclude that oral supplementation with Brome-Inf emerges as a promising co-management option for OE for its action on pain and edema, potentially enhancing the quality of life for affected children. Importantly, due to its well-balanced fruity flavor, the palatability of Brome-Inf was appreciated, ensuring optimal patient compliance and treatment safety.
2025
69
19
1
9
https://onlinelibrary.wiley.com/doi/epdf/10.1002/mnfr.70148
Ananas comosus; bromelain; non‐steroidal anti‐inflammatory drugs; nutraceutical; pain rating scales; pediatric patients
Colletti, Alessandro; Sangiorgio, Luciano; Martelli, Alma; Pellizzato, Marzia; Cravotto, Giancarlo
File in questo prodotto:
File Dimensione Formato  
Molecular Nutrition Food Res - 2025 - Colletti - Bromelain‐Rich Pineapple Extract for the Treatment of Pediatric Patients.pdf

Accesso aperto

Descrizione: pdf
Tipo di file: PDF EDITORIALE
Dimensione 899.67 kB
Formato Adobe PDF
899.67 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/2117256
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact